BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

533 related articles for article (PubMed ID: 27539693)

  • 1. Experience With the Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold in Arteries Below the Knee: 12-Month Clinical and Imaging Outcomes.
    Varcoe RL; Schouten O; Thomas SD; Lennox AF
    JACC Cardiovasc Interv; 2016 Aug; 9(16):1721-8. PubMed ID: 27539693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three-Year Results of the Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold in Infrapopliteal Arteries.
    Varcoe RL; Thomas SD; Lennox AF
    J Endovasc Ther; 2018 Dec; 25(6):694-701. PubMed ID: 30205736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial experience with the absorb bioresorbable vascular scaffold below the knee: six-month clinical and imaging outcomes.
    Varcoe RL; Schouten O; Thomas SD; Lennox AF
    J Endovasc Ther; 2015 Apr; 22(2):226-32. PubMed ID: 25809367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Everolimus-Eluting Stent for Patients With Critical Limb Ischemia and Infrapopliteal Arterial Occlusive Disease.
    Giaquinta A; Vincenzo A; De Marco E; Veroux M; Veroux P
    Vasc Endovascular Surg; 2017 Feb; 51(2):60-66. PubMed ID: 28100126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioresorbable Everolimus-Eluting Vascular Scaffold for Patients With Peripheral Artery Disease (ESPRIT I): 2-Year Clinical and Imaging Results.
    Lammer J; Bosiers M; Deloose K; Schmidt A; Zeller T; Wolf F; Lansink W; Sauguet A; Vermassen F; Lauwers G; Scheinert D; Popma JJ; McGreevy R; Rapoza R; Schwartz LB; Jaff MR
    JACC Cardiovasc Interv; 2016 Jun; 9(11):1178-87. PubMed ID: 27282601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early and Midterm Experience With the Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold in Asian Patients With Chronic Limb-Threatening Ischemia: One-Year Clinical and Imaging Outcomes From the DISAPEAR Registry.
    Kum S; Ipema J; Chun-Yin DH; Lim DM; Tan YK; Varcoe RL; Hazenberg CEVB; Ünlü Ç
    J Endovasc Ther; 2020 Aug; 27(4):616-622. PubMed ID: 32469296
    [No Abstract]   [Full Text] [Related]  

  • 7. One-Year Clinical Outcomes of the Legflow Drug-Coated Balloon for the Treatment of Femoropopliteal Occlusions Registry.
    Stabile E; Gerardi D; Magliulo F; Zhelev D; Chervenkoff V; Taeymans K; Kotasov D; Goverde P; Giugliano G; Trimarco B; Esposito G
    J Endovasc Ther; 2019 Feb; 26(1):26-30. PubMed ID: 30760132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and one-year outcomes of Luminor® paclitaxel-coated drug-eluting balloon in the treatment of popliteal artery atherosclerosis lesions.
    Pecoraro F; Dinoto E; Pakeliani D; Mirabella D; Ferlito F; Bajardi G
    Ann Vasc Surg; 2021 Oct; 76():370-377. PubMed ID: 33951533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three-Year Sustained Clinical Efficacy of Drug-Coated Balloon Angioplasty in a Real-World Femoropopliteal Cohort.
    Torsello G; Stavroulakis K; Brodmann M; Micari A; Tepe G; Veroux P; Benko A; Choi D; Vermassen FEG; Jaff MR; Guo J; Dobranszki R; Zeller T;
    J Endovasc Ther; 2020 Oct; 27(5):693-705. PubMed ID: 32583749
    [No Abstract]   [Full Text] [Related]  

  • 10. Single-Center Experience With Lutonix Drug-Coated Balloons in Infrapopliteal Arteries.
    Steiner S; Schmidt A; Bausback Y; Bräunlich S; Ulrich M; Banning-Eichenseer U; Scheinert D
    J Endovasc Ther; 2016 Jun; 23(3):417-23. PubMed ID: 27099285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes After Drug-Coated Balloon Treatment of Femoropopliteal Lesions in Patients With Critical Limb Ischemia: A Post Hoc Analysis From the IN.PACT Global Study.
    Reijnen MMPJ; van Wijck I; Zeller T; Micari A; Veroux P; Keirse K; Lee SW; Li P; Voulgaraki D; Holewijn S
    J Endovasc Ther; 2019 Jun; 26(3):305-315. PubMed ID: 30931726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two-year follow-up of bioresorbable vascular scaffolds in severe infra-popliteal arterial disease.
    Dia A; Venturini JM; Kalathiya RJ; Besser S; Estrada JR; Friant J; Paul J; Blair JE; Nathan S; Shah AP
    Vascular; 2021 Jun; 29(3):355-362. PubMed ID: 32921290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Performance of Paclitaxel Drug-Eluting Bare Metal Stenting (Zilver PTX) for the Treatment of Femoropopliteal Occlusive Disease.
    Tran K; Ullery BW; Kret MR; Lee JT
    Ann Vasc Surg; 2017 Jan; 38():90-98. PubMed ID: 27554688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-Coated Balloon Treatment of Femoropopliteal Lesions for Patients With Intermittent Claudication and Ischemic Rest Pain: 2-Year Results From the IN.PACT Global Study.
    Micari A; Brodmann M; Keirse K; Peeters P; Tepe G; Frost M; Wang H; Zeller T;
    JACC Cardiovasc Interv; 2018 May; 11(10):945-953. PubMed ID: 29798770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-eluting balloons for femoropopliteal lesions show better performance in de novo stenosis or occlusion than in restenosis.
    Herten M; Torsello GB; Schönefeld E; Imm B; Osada N; Stahlhoff S
    J Vasc Surg; 2015 Feb; 61(2):394-9. PubMed ID: 25307133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One-Year Outcomes of the Paclitaxel-Eluting, Self-Expanding Stentys Stent System in the Treatment of Infrapopliteal Lesions in Patients With Critical Limb Ischemia.
    Bosiers M; Callaert J; Keirse K; Hendriks JMH; Peeters P; Verbist J; Maene L; Beelen R; Deloose K
    J Endovasc Ther; 2017 Jun; 24(3):311-316. PubMed ID: 28351310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. German Center Subanalysis of the LEVANT 2 Global Randomized Study of the Lutonix Drug-Coated Balloon in the Treatment of Femoropopliteal Occlusive Disease.
    Scheinert D; Schmidt A; Zeller T; Müller-Hülsbeck S; Sixt S; Schröder H; Weiss N; Ketelsen D; Ricke J; Steiner S; Rosenfield K
    J Endovasc Ther; 2016 Jun; 23(3):409-16. PubMed ID: 27117972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paclitaxel-Coated Balloon in Infrapopliteal Arteries: 12-Month Results From the BIOLUX P-II Randomized Trial (BIOTRONIK'S-First in Man study of the Passeo-18 LUX drug releasing PTA Balloon Catheter vs. the uncoated Passeo-18 PTA balloon catheter in subjects requiring revascularization of infrapopliteal arteries).
    Zeller T; Beschorner U; Pilger E; Bosiers M; Deloose K; Peeters P; Scheinert D; Schulte KL; Rastan A; Brodmann M
    JACC Cardiovasc Interv; 2015 Oct; 8(12):1614-22. PubMed ID: 26493253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single arm retrospective study of bioresorbable vascular scaffolds to treat patients with severe infrapopliteal arterial disease.
    Dia A; Venturini JM; Kalathiya R; Besser S; Estrada R; Friant J; Paul J; Blair JE; Nathan S; Shah AP
    Catheter Cardiovasc Interv; 2019 Dec; 94(7):1028-1033. PubMed ID: 31617294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High dose-rate brachytherapy for the treatment of lower extremity in-stent restenosis.
    Ho KJ; Devlin PM; Madenci AL; Semel ME; Gravereaux EC; Nguyen LL; Belkin M; Menard MT
    J Vasc Surg; 2017 Mar; 65(3):734-743. PubMed ID: 27986482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.